[{"arm_notes": "", "treatment_id": null, "treatment_name": "The study population includes 444 healthy adults more than 18 years who completed primary series of COVID-19 vaccine with either homologous primary vaccination with 2 doses of ChAdOx-1 or Heterologous Sinovac-AstraZeneca at least 90 days before screening. These 2 groups of participants will receive COVID-19 Vaccine HIPRA (40 micrograms; i.m.) as the booster vaccination.;Experimental Biological/Vaccine;COVID-19 Vaccine HIPRA", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "homologous or heterologous primary vaccination", "treatment_id": 1828, "treatment_name": "Phh-1v", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]